NZ729803A - A method for the treatment of motor neuron diseases - Google Patents
A method for the treatment of motor neuron diseasesInfo
- Publication number
- NZ729803A NZ729803A NZ729803A NZ72980315A NZ729803A NZ 729803 A NZ729803 A NZ 729803A NZ 729803 A NZ729803 A NZ 729803A NZ 72980315 A NZ72980315 A NZ 72980315A NZ 729803 A NZ729803 A NZ 729803A
- Authority
- NZ
- New Zealand
- Prior art keywords
- motor neuron
- neuron diseases
- treatment
- levosimendan
- active metabolite
- Prior art date
Links
- 208000005264 motor neuron disease Diseases 0.000 title abstract 3
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 abstract 2
- WHXMKTBCFHIYNQ-SECBINFHSA-N levosimendan Chemical compound C[C@@H]1CC(=O)NN=C1C1=CC=C(NN=C(C#N)C#N)C=C1 WHXMKTBCFHIYNQ-SECBINFHSA-N 0.000 abstract 2
- 229960000692 levosimendan Drugs 0.000 abstract 2
- 239000002207 metabolite Substances 0.000 abstract 2
- 239000004480 active ingredient Substances 0.000 abstract 1
- 210000002027 skeletal muscle Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/06—Anabolic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FI20140278 | 2014-10-15 | ||
| PCT/FI2015/000039 WO2016059287A1 (fr) | 2014-10-15 | 2015-10-14 | Le lévosimendan et son utilisation dans le traitement des maladies des motoneurones (par exemple, la sla) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ729803A true NZ729803A (en) | 2023-07-28 |
Family
ID=54705650
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ729803A NZ729803A (en) | 2014-10-15 | 2015-10-14 | A method for the treatment of motor neuron diseases |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US10357492B2 (fr) |
| EP (1) | EP3206690A1 (fr) |
| JP (1) | JP6688295B2 (fr) |
| KR (1) | KR102560182B1 (fr) |
| CN (1) | CN107072994B (fr) |
| AU (1) | AU2015332367B2 (fr) |
| CA (1) | CA2963179C (fr) |
| MX (1) | MX2017004842A (fr) |
| NZ (1) | NZ729803A (fr) |
| RU (1) | RU2706001C2 (fr) |
| WO (1) | WO2016059287A1 (fr) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3993773A1 (fr) | 2019-07-01 | 2022-05-11 | Orion Corporation | Procédés d'administration de(r)-n-[4-(1,4,5,6-tétrahydro-6-oxo-3-pyridazinyl)phényl]acétamide |
| JPWO2021075477A1 (fr) * | 2019-10-16 | 2021-04-22 | ||
| CA3161960A1 (fr) | 2019-12-16 | 2021-06-24 | Tenax Therapeutics, Inc. | Levosimendan pour traiter l'hypertension pulmonaire accompagnee d'une insuffisance cardiaque au moyen d'une fraction d'ejection preservee (ph-hfpef) |
| CN115518037A (zh) * | 2022-10-14 | 2022-12-27 | 上药东英（江苏）药业有限公司 | 一种安全质量稳定的左西孟旦注射剂组合物及其制备方法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI20011465A0 (fi) * | 2001-07-04 | 2001-07-04 | Orion Corp | Pyridatsinonijohdannaisen uusi käyttö |
| US9867837B2 (en) * | 2011-03-01 | 2018-01-16 | Pharnext | Compositions for treating neurological disorders |
| UA113165C2 (xx) | 2011-03-01 | 2016-12-26 | Застосування комбінації баклофену і акампросату для лікування неврологічних захворювань та композиція, яка містить баклофен і акампросат |
-
2015
- 2015-10-14 WO PCT/FI2015/000039 patent/WO2016059287A1/fr active Application Filing
- 2015-10-14 NZ NZ729803A patent/NZ729803A/en unknown
- 2015-10-14 US US15/518,949 patent/US10357492B2/en active Active
- 2015-10-14 EP EP15801474.6A patent/EP3206690A1/fr not_active Withdrawn
- 2015-10-14 JP JP2017519906A patent/JP6688295B2/ja active Active
- 2015-10-14 CN CN201580055558.2A patent/CN107072994B/zh active Active
- 2015-10-14 MX MX2017004842A patent/MX2017004842A/es unknown
- 2015-10-14 AU AU2015332367A patent/AU2015332367B2/en active Active
- 2015-10-14 RU RU2017116157A patent/RU2706001C2/ru active
- 2015-10-14 KR KR1020177012960A patent/KR102560182B1/ko active IP Right Grant
- 2015-10-14 CA CA2963179A patent/CA2963179C/fr active Active
Also Published As
| Publication number | Publication date |
|---|---|
| KR20170066647A (ko) | 2017-06-14 |
| RU2017116157A3 (fr) | 2019-04-11 |
| US10357492B2 (en) | 2019-07-23 |
| CA2963179A1 (fr) | 2016-04-21 |
| AU2015332367B2 (en) | 2020-05-14 |
| AU2015332367A1 (en) | 2017-04-06 |
| CN107072994B (zh) | 2020-04-21 |
| RU2706001C2 (ru) | 2019-11-13 |
| CN107072994A (zh) | 2017-08-18 |
| MX2017004842A (es) | 2017-06-22 |
| US20170231987A1 (en) | 2017-08-17 |
| WO2016059287A1 (fr) | 2016-04-21 |
| KR102560182B1 (ko) | 2023-07-28 |
| CA2963179C (fr) | 2023-08-29 |
| RU2017116157A (ru) | 2018-11-15 |
| EP3206690A1 (fr) | 2017-08-23 |
| JP2017531006A (ja) | 2017-10-19 |
| JP6688295B2 (ja) | 2020-04-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12019500095A1 (en) | Compounds, compositions, and methods for the treatment of disease | |
| TN2018000005A1 (en) | Agents, uses and methods for the treatment of synucleinopathy | |
| EP3265053A4 (fr) | Procédés de traitement de la peau | |
| GB2541571A (en) | Pharmaceutical compositions | |
| MX2017010150A (es) | Bacterias probioticas recombinantes. | |
| EP3149205A4 (fr) | Procédé de diagnostic, de traitement et de prévention de la maladie de parkinson | |
| MX2018008105A (es) | Compuestos inhibidores de metaloenzima. | |
| PH12018500578A1 (en) | Methods of treating inflammatory diseases | |
| MX2020006237A (es) | Compuestos para el tratamiento de enfermedades relacionadas con la expresion de dux4. | |
| EP3386520A4 (fr) | Méthodes de traitement d'une maladie ou d'un trouble oculaire | |
| EP3347844A4 (fr) | Procédé et système pour diagnostiquer une maladie et générer des recommandations de traitement | |
| MX2017016114A (es) | Metodos para tratar o prevenir una proteopatia. | |
| MY195000A (en) | Method for the treatment of neurological disease | |
| WO2019173795A3 (fr) | Réduction du fragment c99 de l'app localisé sur la membrane er-mam et méthodes de traitement de la maladie d'alzheimer | |
| MX2018005987A (es) | Compuestos heterociclicos para el tratamiento de enfermedades. | |
| HK1253299A1 (zh) | 一種通過基因治療治療眼疾病的改進方法 | |
| NZ729803A (en) | A method for the treatment of motor neuron diseases | |
| HUE051205T2 (hu) | Eljárások legalább egy emulzió kezelésére villamos tér alkalmazásával | |
| EP3253401A4 (fr) | Méthode de traitement de maladies | |
| EP3310377A4 (fr) | Méthode de traitement de la maladie de crohn | |
| EP3256137A4 (fr) | Méthode de traitement de l'insuffisance cardiaque | |
| TW201613610A (en) | Use of ginsenoside M1 for treating lupus nephritis | |
| ZA201903804B (en) | Method for producing hydrophobising leather treatment agents | |
| EP3730144A4 (fr) | Agent pour le traitement d'une maladie du système nerveux | |
| HK1247884A1 (zh) | 用於皮膚的美容處理的方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed |